In our work, we found that PKIB plays an important oncogenic role in BLCA by inhibiting PKA kinase activity and reducing the phosphorylation of a new substrate target protein, HSP27, which confirms the biological function of PKIB as a specific PKA inhibitor. This evidence concerns the gene HSPB1 and bladder transitional cell carcinoma.